Author:
Kanemo Philip,Musa Keffi Mubarak,Deenadayalan Vaishali,Litvin Rafaella,Odeyemi Olubunmi Emmanuel,Shaka Abdultawab,Baskaran Naveen,Shaka Hafeez
Abstract
Pancreatic cancer (PC) remains one of the most challenging diseases, with a very poor 5-year overall survival of around 11.5%. Kirsten rat sarcoma virus (KRAS) mutation is seen in 90%-95% of PC patients and plays an important role in cancer cell proliferation, differentiation, metabolism, and survival, making it an essential mutation for targeted therapy. Despite extensive efforts in studying this oncogene, there has been little success in finding a drug to target this pathway, labelling it for decades as “undruggable”. In this article we summarize some of the efforts made to target the KRAS pathway in PC, discuss the challenges, and shed light on promising clinical trials.
Publisher
Baishideng Publishing Group Inc.
Reference34 articles.
1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Mar 11, 2020. [cited Feb 23, 2023]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
2. World Health Organization; WHO Coronavirus (COVID-19) Dashboard. Feb 23, 2022. [cited Feb 25, 2022]. Available from: https://covid19.who.int
3. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention
4. Two Years into the COVID-19 Pandemic: Lessons Learned
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献